Peptipedia
Growth HormoneIn Clinical TrialsClinical Trials

Ipamorelin

Also known as IPAM, NNC 26-0161

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.

Investigational - Phase II trials discontinued (failed to meet efficacy endpoints)
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

200-300 mcg, 2-3x daily

Frequency

2-3x daily

Duration

8-12 weeks typical

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 200-300 mcg, 2-3x daily via Subcutaneous injection, 2-3x daily. Dose range: 100-500 mcg per dose. Duration: 8-12 weeks typical.

Timing & Administration

Administer via Subcutaneous injection. Frequency: 2-3x daily.

Mechanism of Action

Binds to ghrelin receptors in the pituitary gland to trigger GH release while avoiding significant stimulation of ACTH, cortisol, prolactin, or aldosterone.

Research Summary

Evidence level: clinical trials. Clinical status: Investigational - Phase II trials discontinued (failed to meet efficacy endpoints).

Side Effects & Safety

Important Warnings

  • Contraindicated with active malignancy
Injection site reactions
headache
nausea
increased appetite
water retention
temporary joint stiffness

References

No references available.

Related Peptides

Browse all →
CJC-1295Growth Hormone

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary.

View profile
TesamorelinGrowth Hormone

An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

View profile
GHRP-6Growth Hormone

One of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite.

View profile